Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

7.88  +0.03 (+0.38%)

After market: 7.8 -0.08 (-1.02%)

Fundamental Rating

3

Taking everything into account, RCUS scores 3 out of 10 in our fundamental rating. RCUS was compared to 568 industry peers in the Biotechnology industry. RCUS may be in some trouble as it scores bad on both profitability and health. RCUS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCUS has reported negative net income.
RCUS had a negative operating cash flow in the past year.
In the past 5 years RCUS reported 4 times negative net income.
In multiple years RCUS reported negative operating cash flow during the last 5 years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

The Return On Assets of RCUS (-24.61%) is better than 72.89% of its industry peers.
RCUS has a Return On Equity of -58.35%. This is in the better half of the industry: RCUS outperforms 60.74% of its industry peers.
Industry RankSector Rank
ROA -24.61%
ROE -58.35%
ROIC N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCUS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RCUS has more shares outstanding
Compared to 1 year ago, RCUS has a worse debt to assets ratio.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.47, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
RCUS has a better Altman-Z score (-0.47) than 62.50% of its industry peers.
RCUS has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, RCUS is doing worse than 65.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.47
ROIC/WACCN/A
WACC10.26%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

RCUS has a Current Ratio of 4.50. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS has a Current ratio (4.50) which is comparable to the rest of the industry.
A Quick Ratio of 4.50 indicates that RCUS has no problem at all paying its short term obligations.
RCUS has a Quick ratio of 4.50. This is comparable to the rest of the industry: RCUS outperforms 52.46% of its industry peers.
Industry RankSector Rank
Current Ratio 4.5
Quick Ratio 4.5
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

RCUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.30%, which is quite impressive.
Looking at the last year, RCUS shows a very strong growth in Revenue. The Revenue has grown by 120.51%.
RCUS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 76.65% yearly.
EPS 1Y (TTM)25.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.63%
Revenue 1Y (TTM)120.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-16.13%

3.2 Future

RCUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.06% yearly.
Based on estimates for the next years, RCUS will show a very strong growth in Revenue. The Revenue will grow by 27.23% on average per year.
EPS Next Y-36.04%
EPS Next 2Y-17.4%
EPS Next 3Y-6.97%
EPS Next 5Y8.06%
Revenue Next Year-43.09%
Revenue Next 2Y-15.4%
Revenue Next 3Y-1.1%
Revenue Next 5Y27.23%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as RCUS's earnings are expected to decrease with -6.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.4%
EPS Next 3Y-6.97%

More info and screens

0

5. Dividend

5.1 Amount

RCUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (4/17/2025, 8:04:00 PM)

After market: 7.8 -0.08 (-1.02%)

7.88

+0.03 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners94.92%
Inst Owner Change0%
Ins Owners6.49%
Ins Owner Change4.6%
Market Cap834.02M
Analysts82.11
Price Target33.2 (321.32%)
Short Float %6.89%
Short Ratio7.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.46%
Min EPS beat(2)7.78%
Max EPS beat(2)19.13%
EPS beat(4)4
Avg EPS beat(4)32.67%
Min EPS beat(4)7.78%
Max EPS beat(4)94.85%
EPS beat(8)7
Avg EPS beat(8)20.12%
EPS beat(12)10
Avg EPS beat(12)15.36%
EPS beat(16)11
Avg EPS beat(16)45.13%
Revenue beat(2)1
Avg Revenue beat(2)6.75%
Min Revenue beat(2)-11.8%
Max Revenue beat(2)25.3%
Revenue beat(4)3
Avg Revenue beat(4)95.65%
Min Revenue beat(4)-11.8%
Max Revenue beat(4)319.8%
Revenue beat(8)5
Avg Revenue beat(8)49.59%
Revenue beat(12)8
Avg Revenue beat(12)39.97%
Revenue beat(16)9
Avg Revenue beat(16)75.53%
PT rev (1m)-2.56%
PT rev (3m)-4.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.49%
EPS NY rev (1m)10.21%
EPS NY rev (3m)14.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.02%
Revenue NY rev (1m)-7.48%
Revenue NY rev (3m)-29.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-3.1
EYN/A
EPS(NY)-4.22
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS2.44
BVpS4.58
TBVpS4.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.61%
ROE -58.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60%
Cap/Sales 2.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.5
Quick Ratio 4.5
Altman-Z -0.47
F-Score4
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.63%
EPS Next Y-36.04%
EPS Next 2Y-17.4%
EPS Next 3Y-6.97%
EPS Next 5Y8.06%
Revenue 1Y (TTM)120.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-16.13%
Revenue Next Year-43.09%
Revenue Next 2Y-15.4%
Revenue Next 3Y-1.1%
Revenue Next 5Y27.23%
EBIT growth 1Y8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.75%
EBIT Next 3Y-8.81%
EBIT Next 5YN/A
FCF growth 1Y46.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.44%
OCF growth 3YN/A
OCF growth 5YN/A